Fungal Genomics Mining for Drugs
Deep bioinformatic mining of unexpressed, cryptic biosynthetic gene clusters (BGCs) across fungal genomes, combined with synthetic promoter engineering and heterologous expression in optimized fungal chassis to unlock novel complex natural products as antimicrobial and antineoplastic leads.
1 · What it gives
Fungal Genomics Mining for Drugs represents a high-capacity industrial biomanufacturing domain encompassing microbial submerged fermentation APIs, fungal natural product mining, plant cell suspension culture, and geroprotective longevity therapeutics. By replacing destructive chemical synthesis or scarce wild-plant harvesting with sustainable, tightly controlled bioreactor cultivation, the platform produces complex bioactive macrocycles, glycosylated natural actives, and longevity-modulating molecules at commercial scale. Advanced strain engineering, media optimization, and automated metabolic feeding yield consistent multi-ton batches compliant with international pharmacopeial monographs.
The operational spectrum is anchored by 50–100 m3 industrial stainless-steel fermenters operating under closed aseptic aeration (dissolved oxygen >30%, air flow up to 1.5 vvm) and automated glucose/dextrose fed-batch control. Downstream recovery integrates broth conditioning via flocculation, rotary vacuum drum filtration or continuous disc-stack centrifugation to separate cellular mycelium, and macroporous adsorption resin capture or liquid-liquid solvent extraction. Crude extracts undergo multi-stage crystallization, activated carbon decolorization, and cleanroom vacuum paddle drying, yielding crystalline active pharmaceutical ingredients (APIs) at >99.0% chemical purity with residual solvents well below ICH Q3C limits.
The key directions of this technology are:
- Metabolic Pathway Engineering in Fungal Genomics Mining for Drugs: Rewiring actinomycete or fungal precursor flux using CRISPR-Cas9 and synthetic promoter libraries to boost secondary metabolite yield by >300%.
- Industrial Submerged Aerobic Fermentation: Executing continuous fed-batch fermentation in 50,000L–100,000L stainless-steel fermenters with automated respiratory quotient (RQ) feedback.
- Macroporous Adsorption Resin Chromatography: Deploying polymeric non-ionic adsorbent resins (such as Amberlite XAD) to selectively capture target actives while discarding hydrophilic media impurities.
- Controlled Supercritical & Reactive Crystallization: Conducting precise anti-solvent or temperature-shift crystallization to achieve uniform crystal size distribution (<50 um) and optimal polymorphic purity.
Sectoral value chain#
┌────────────────────────────────────────────────────────┐
│ Tier 1: Master Spore Bank & Seed Inoculum Train │
│ (Cryopreserved actinomycete/fungal/plant cell stocks) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 2: 50–100 m3 Industrial Aerobic Fermenter │
│ (Sterile air sparging, automated dextrose fed-batch) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 3: Broth Flocculation & Mycelial Separation │
│ (Rotary vacuum drum filtration / disc centrifugation) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 4: Solvent Extraction / Resin Adsorption Capture │
│ (Ethyl acetate / macroporous polymeric resin elution) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 5: Carbon Decolorization & Multi-Stage Crystall. │
│ (Anti-solvent precipitation, vacuum paddle drying) │
└────────────────────────────────────────────────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Strain Cryopreservation & Inoculum Expansion | Maintenance of high-yielding production strains in vapor-phase nitrogen and seed expansion in shake flasks and seed fermenters. | In: Working Cell Bank ampoules, sterile nutrient broth, seed fermenters. Out: High-viability vegetative mycelial inoculum broth. |
| Industrial Scale Submerged Cultivation | Aerobic fermentation in 50 m3–100 m3 stainless-steel fermenters with automated dissolved oxygen and pH control. | In: Sterile carbohydrate feed, ammonia water, anti-foam agents. Out: Mature fermentation broth containing target API at 15–30 g/L. |
| Cellular Harvest & Primary Liquid-Solid Separation | Broth conditioning with polymeric flocculants followed by rotary vacuum drum filtration (RVDF) to remove mycelia. | In: Whole fermentation broth, filter aids (diatomite), flocculants. Out: Clarified aqueous filtrate containing dissolved active metabolite. |
| Target Extraction & Adsorptive Enrichment | Counter-current solvent extraction or macroporous resin column capture followed by alcohol elution. | In: Extraction solvents (ethyl acetate), macroporous resins, ethanol. Out: Concentrated rich extract pool at >85% chromatographic purity. |
| Decolorization, Crystallization & Micronization | Treatment with activated carbon, seed-induced crystallization, vacuum drying, and fluid energy jet milling. | In: Rich extract, pharmaceutical-grade activated carbon, nitrogen. Out: Finished crystalline API powder compliant with USP/EP monographs. |
Cross-cutting technologies of the sector:
- Off-Gas Mass Spectrometry (RQ & CER Monitoring): Continuous real-time measurement of carbon dioxide evolution rate (CER) and respiratory quotient to guide feeding transitions.
- Powder X-Ray Diffraction (PXRD) & DSC Polymorph Control: Thermal and crystallographic confirmation guaranteeing the thermodynamic stability and bioequivalence of crystalline forms.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 4 steps
- 1Cryptic BGC bioinformatic predictionMining tens of thousands of fungal genomes using machine learning algorithms (antiSMASH, BiG-SCAPE) to identify novel non-ribosomal peptide (NRPS) and polyketide (PKS) clusters.
- 2Epigenetic and promoter refactoringSynthesizing synthetic promoter cassettes and CRISPR-Cas9 activation systems to override native chromatin silencing.
- 3Heterologous expression in fungal hostsTransferring multi-gene biosynthetic clusters into high-yielding, genetically clean Aspergillus or Pichia chassis organisms.
- 4High-resolution structure and screeningIsolating novel metabolites via preparative HPLC, determining 3D structures via NMR/cryo-electron diffraction, and screening against multidrug-resistant pathogens.
4 · Who delivers
Matched suppliers (matched automatically)
| Novartis | Switzerland | Producer | active |
| Lonza Group | Switzerland | Producer | active |
| HLB Genex (ex-GenoFocus) | South Korea | Producer | active |
| Rev Genomics | United States | Producer | active |
| LipiTune GmbH | Germany | Producer | active |
| Well Shine Biotechnology Development Co., Ltd. | Taiwan | Producer | active |
| Loam Bio | Australia | Producer | active |
| Endolith | United States | Producer | active |
| HSsynbiotech 合生科技 | China | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Novartis | 🇨🇭 Switzerland | Innovative Medicines & Targeted Therapies | Industrial scalable manufacturing & QbD validation | commercial |
| Roche / Genentech | 🇨🇭 Switzerland | Biopharma Discovery & Diagnostic Platforms | Industrial scalable manufacturing & QbD validation | commercial |
| Lonza Group | 🇨🇭 Switzerland | Custom Biologics CDMO & Ibex Solutions | Industrial scalable manufacturing & QbD validation | commercial |
| Lifemine Therapeutics | 🇺🇸 United States | Proprietary Therapeutics & Process Infrastructure | Industrial scalable manufacturing & QbD validation | clinical |
| F2G | 🇺🇸 United States | Proprietary Therapeutics & Process Infrastructure | Industrial scalable manufacturing & QbD validation | clinical |
| Metagenomi Therapeutics | 🇺🇸 United States | Proprietary Therapeutics & Process Infrastructure | Industrial scalable manufacturing & QbD validation | clinical |
| Lonza Group | 🇨🇭 Switzerland | Custom Biologics CDMO & Ibex Solutions | Industrial scalable manufacturing & QbD validation | commercial |
5 · Rules & route to market
United States
FDA CDER API DMF filings, metabolic health boom, and cGMP imports#
- FDA Drug Master File (DMF) Standards: Strict Type II DMF technical filing requirements with comprehensive impurity profiling, genotoxic impurity limits, and stability testing.
- Metabolic Health & Longevity Boom: Explosive market growth for fermentation-derived geroprotectors, metabolic enzyme inhibitors, and longevity modulators.
- Domestic Specialty Biomanufacturing: Emerging US federal initiatives supporting domestic synthetic biology fermentation infrastructure for critical healthcare APIs.
European Union
European CEP certification, EDQM pharmacopeial standards, Swiss quality#
- EDQM Certificate of Suitability (CEP): European Directorate for the Quality of Medicines certifying compliance of fermentation APIs with Ph. Eur. standards.
- Swiss & German Premium Synthesis: High-value specialty biopharma operations focusing on ultra-pure immunosuppressants and plant cell culture bioactives.
- Stringent Environmental & REACH Directives: Complete elimination of chlorinated extraction solvents in favor of bio-based green solvents across European facilities.
China
Global fermentation superpower, green industrial upgrades, CDE filings#
- World-Leading Fermentation Capacity: China operating the world’s largest fermentation bases in Shandong, Zhejiang, and Hebei, supplying >70% of global microbial APIs.
- National Green Bioeconomy Mandates: Massive capital investment in wastewater recycling, membrane separation, and biological deodorization across fermentation plants.
- NMPA Consistency Evaluation: Mandatory bioequivalence and quality consistency evaluation ensuring domestic fermentation APIs match originator brand quality.
6 · Money: tenders & grants
| Grant | Developing novel recycling technologies for complex plastic materials applying biotech solutions European Commission · EU | Sep 22, 2027 303 days |
| Grant | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States | Oct 15, 2027 326 days |
| Grant | Enhancing ecodesign and circularity of construction products European Commission · EU | Sep 22, 2027 303 days |
| Grant | NSF Scholarships in Science, Technology, Engineering, and Mathematics Program U.S. National Science Foundation · United States | Mar 2, 2027 99 days |
| Grant | Pioneering Aerospace Capabilities, Engineering and Research (PACER) Air Force -- Research Lab · United States | May 10, 2043 6012 days |
7 · Tech stack & innovations
- High-Yield Fermentation Bioprocess in Fungal Genomics Mining for Drugs:
- Utilizes mutagenized or genetically engineered actinomycete strains (Streptomyces or Actinoplanes) with targeted promoter knock-ins.
- Delivers exceptional volumetric productivity (>20 g/L) with minimal co-production of related structural isomers.
- Large-Scale 100 m3 Stirred-Tank Bioreactors:
- Equipped with multi-impeller Rushton turbines and hydrofoil mixers delivering power inputs up to 3 kW/m3.
- In-line PAT sensors delivering closed-loop feedback control over sterile feed dosing, cooling jacket temperature, and agitation speed.
- Continuous Anti-Solvent Crystallization:
- Controlled temperature-drop and anti-solvent addition curves maintaining metastable zone width to prevent spontaneous secondary nucleation.
- Generates large, uniform crystalline needles or prisms with low surface area, facilitating rapid filtration and washing.
Sources 1 · 0 independent · 1 producer sites
Producers' own sites 1
- www.swissbiotech.org producer checked 2026-11-22